Focused on microbiome platform technologies for development of immunological-based therapies, Rise Therapeutics LLC is the latest spin-off and partnership implemented by Seattle-based Vertici, LLC - itself an active SBIR-involved entity in its own right. Focused on developing microbiome-based, immunological therapies using key microbiome-related intellectual property and technologies incubated at Virtici to support the orally-delivered, biological medicines, Rise Therapeutics is developing immune-modulating therapies based upon a vast new array of targets. Leveraging its proprietary TriPartite X (TPX) platform to deliver targeted biologics orally -- a novel step forward in the context of protein-based medicines. -- as a delivery vehicle,TPX is well suited to deliver any biological therapy orally. Two product candidates initially have been selected for clinical testing with the identification and characterization of other possible novel targets underway. The microbiome of the gut is a critical immunological ecosystem says Gary Fanger, President and CEO of Rise Therapeutics. By understanding how the microbiome influences our immune system via the intestinal tract, we can design appropriate immunological medicines that can treat a variety of diseases including inflammation, autoimmunity and cancer. With our proprietary TPX delivery platform, we can exploit these microbiome discoveries to deliver biological-based medicines orally that target key pathways in the intestinal tract. Rises proprietary TPX technology is based upon work from the laboratory of Dr. David Pascual, Professor at the University of Florida. The Intellectual property to support the platform and initial therapeutic programs were licensed from the University of Florida and Montana State University. With these novel scientific discoveries, Rise is rapidly moving its first program into clinic development. In addition, Rise is expanding the core foundation technologies and working with its partners in the context of more broadly exploiting TPX to deliver oral biological therapies. Rise Therapeutics represents another spin-out from the three affiliate companies, Virtici, Celdara Medical, and MBV. With a goal of enhancing industry innovation, Virtici, Celdara Medical, and MBV specialize in identifying and developing novel early-stage innovations from research institutions from across North America and increasingly, beyond. Partnerships and new spin-outs are core to accelerating the value base of the model from these three affiliated companies. ABOUT RISE THERAPEUTICS, LLC At the crossroads of the microbiome and immunology, Rise Therapeutics is developing immunologically-directed biological therapies using a unique and proprietary oral delivery platform. Based in Rockville, Maryland, Rise leverages its target discovery expertise to understand microbiota gut biology as it relates to regulation of the immune system. Utilizing these biological discoveries to identify new immune regulatory pathways Rise develops immune modulatory drugs for therapy of autoimmunity, inflammatory disease, and cancer. With its proprietary Tripartite X (TPX) platform, Rise can deliver these first-in-class biological therapies orally.
